Targeting bone diseases.

Latest News

Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)
> Read the Press Release

Enobia launches Hypophosphatasia.com, a comprehensive new resource for patients and families living with HPP.
> Go to Hypophosphatasia.com

Dr. Philippe Crine, VP and Chief Scientific Officer of Enobia received the CP LeBlond Award for his exceptional bone research.

Stay Informed

Twitter MySpace Facebook RSS
Receive the latest news and updates on hypophosphatasia.
I am a:
Privacy & Confidentiality Policy
Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted A medical treatment that replaces an enzyme in patients who either lack or have a deficient form of the particular enzyme.enzyme replacement therapy for A rare, inherited, and sometimes fatal metabolic bone disease characterized by poor bone mineralization and profound skeletal defects.hypophosphatasia and is currently in Phase 2 clinical studies.



"What is
A rare, inherited, and sometimes fatal metabolic bone disease characterized by poor bone mineralization and profound skeletal defects.Hypophosphatasia?"

Results of HIPS Patient Survey
 
Cartoon by BrainPOP
All rights reserved